The Evidence Is in

The JADA System was evaluated in a US clinical trial, the PEARLE study.

Not actual patient

The PEARLE Study

The PEARLE study was a prospective, multi-center, pivotal, single-arm study designed to assess the safety and effectiveness of the JADA System in treating primary postpartum hemorrhage and abnormal postpartum uterine bleeding, and enrolled 107 subjects.1

Read the Publication
Pearle Study Logo

The JADA System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.

Before using JADA, please read the contraindications, warnings, precautions, and other important information in the Instructions for Use.

At controlling postpartum uterine bleeding

In the PEARLE study, 94% of participants met the primary end point: bleeding was controlled successfully with JADA, and no further intervention was required.1


Users said they would recommend the JADA System

Highly recommended among surveyed clinical investigators, in most cases using JADA for the first time.1,2


In nearly every case, investigators rated JADA easy to use

Highly recommended among surveyed clinical investigators, in most cases using JADA for the first time.1,2


Bleeding Was Controlled Within 3 Minutes (Median)1

1 Minute (median time)

Uterine Collapse Observed

3 Minutes (median time)

Bleeding Controlled

Approximately 3.2 Hours Later, Treatment Completed and Device Removed

Safety Profile2

There were no adverse events deemed definitely related to the device or the procedure and there was a low rate of possibly device-related adverse events.

  • 5 possibly device-related adverse events were rated as “moderate” and no event was rated as “severe.”
  • 3 moderate events were cases of endometritis, which is a known risk of long labor, vaginal exam, and postpartum hemorrhage.
Not actual patient

Demographics and Obstetric History of PEARLE Subjects1 (N=107)

JADA was studied in a diverse patient population with representation of high-risk subgroups.


Bleeding Was Controlled Within 3 Minutes


  • American Indian/
    Alaskan Native: 1%
  • Refused: 2%
  • Other: 8%
  • Asian: 8%
  • Black: 24%
  • White: 57%


  • Hispanic: 15%
  • Non-Hispanic: 82%
  • Other: 1%
  • Refused: 2%

*Race and ethnicity categories were collected according to National Institutes of Health standards. “Other” as a category was included by patient self-report.

Patient Characteristics

16% (9)

Postpartum hemorrhage at previous delivery*

36% (39)

Baseline anemia

23% (25)

Preeclampsia (this pregnancy)

10% (11)


*Includes participants with a previous delivery in the denominator.

Baseline and chronic anemia are defined by site-specific protocol and diagnosis.

Get in Touch

If you are a healthcare professional interested in bringing JADA to your facility, click below to be contacted by the representative in your area.


  1. D'Alton ME, Rood KM, Smid MC, et al. Intrauterine vacuum-induced hemorrhage-control device for rapid treatment of postpartum hemorrhage. Obstet Gynecol. 2020;136(5):882-891. doi:10.1097/AOG.0000000000004138
  2. Data available on request from Organon Professional Services-DAP (Marketing Operations), 30 Hudson St., Jersey City, NJ 07302. Please specify information package US-JDA-110046.